Cargando…
Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
BACKGROUND: Despite improvements in medical care, patients with advanced cancer still experience substantial symptom distress. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. This study aims to define the role of a 1:1 delta-9-t...
Autores principales: | Hardy, Janet, Haywood, Alison, Gogna, Gauri, Martin, Jennifer, Yates, Patsy, Greer, Ristan, Good, Phillip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336664/ https://www.ncbi.nlm.nih.gov/pubmed/32631447 http://dx.doi.org/10.1186/s13063-020-04541-6 |
Ejemplares similares
-
Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD)
por: Good, Phillip, et al.
Publicado: (2019) -
Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature
por: Golombek, Patricia, et al.
Publicado: (2020) -
A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆(9)-tetrahydrocannabinol (THC) by vaporisation
por: Solowij, Nadia, et al.
Publicado: (2014) -
Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?
por: Lachenmeier, Dirk W., et al.
Publicado: (2023) -
Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
por: Hutten, Nadia R. P. W., et al.
Publicado: (2022)